Guangjun Jing
University of Oklahoma Health Sciences Center
6 Papers
Guangjun Jing is an academic researcher from University of Oklahoma Health Sciences Center. The author has contributed to research in topics: Endoplasmic reticulum & Medicine. The author has an hindex of 4, co-authored 4 publications. Previous affiliations of Guangjun Jing include University of Oklahoma.
Chat about Author
Papers
ER Stress and Apoptosis: A New Mechanism for Retinal Cell Death
TL;DR: Recent progress on ER stress and apoptosis in retinal diseases is summarized, focusing on various proapoptotic and antiapoptosis pathways that are activated by the UPR, and how these pathways contribute to ER stress-induced apoptosisIn retinal cells.
ATF4 is a novel regulator of MCP-1 in microvascular endothelial cells
Huibin Huang,Huibin Huang,Guangjun Jing,Joshua J. Wang,Joshua J. Wang,Nader Sheibani,Sarah X. Zhang,Sarah X. Zhang +7 more
TL;DR: A critical role of ATF4 is suggested in the regulation of MCP-1 production in retinal and brain microvascular endothelial cells, which may contribute to inflammation-related endothelial injury in diseases such as diabetic retinopathy.
Identification of p58IPK as a novel neuroprotective factor for retinal neurons.
Evgenii Boriushkin,Joshua Jianxin Wang,Junhua Li,Guangjun Jing,Gail M. Seigel,Sarah X. Zhang +5 more
TL;DR: A protective role of p58(IPK) in retinal neurons is demonstrated, which may act in part through a mechanism involving modulation of ER homeostasis and apoptosis, particularly under conditions of cellular stresses.
A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease
Xiaozhi Hu,Jiajun Fan,Qianqian Ma,Lei Han,Zhonglian Cao,Cailing Xu,Jing Luan,Guangjun Jing,Yanyang Nan,Tao Wu,Ying Zhang,Hanqi Wang,Yuanzhen Zhang,Dianwen Ju +13 more
TL;DR: In this paper , a nanobody-heavy chain antibody (VHH-Fc) was used to inhibit ANGPTL3 for NAFLD treatment, which exhibited high affinities to the Angiopoietin-like protein 3 (ANGPTL), a critical lipid metabolism regulator.
Simultaneous blockade of VEGF-B and IL-17A ameliorated diabetic kidney disease by reducing ectopic lipid deposition and alleviating inflammation response
Zhonglian Cao,Hui Zhao,Jiajun Fan,Yi Shen,Lei Han,Guangjun Jing,Xian Zeng,Xin Jin,Zeguo Zhu,Qi Bian,Yanyang Nan,Xiaozhi Hu,Xiaobin Mei,Dianwen Ju,Ping Yang +14 more
TL;DR: Wang et al. as discussed by the authors showed that renal lipid metabolism abnormality and inflammation significantly changed in diabetic kidney disease (DKD) conditions by mining public transcriptomic data of DKD patient samples, and the potential of a combination therapy, anti-VEGF-B plus anti-IL-17A antibody, was evaluated for DKD treatment.